

**Express Mail Label No.: EV 317 172 776 US**  
**Date of Deposit: August 1, 2003**

**Attorney Docket No. VPI/98-18 DIV US**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: David Lauffer and Michael Mullican  
ASSIGNEE: Vertex Pharmaceuticals Incorporated  
DIVISIONAL OF: 10/039,886 EXAMINER: Charanjit Aulakh  
FILING DATE: Herewith ART UNIT: 1625  
FOR: BICYCLIC DERIVATIVES

August 1, 2003  
Cambridge, Massachusetts 02139-4242

MS Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97.


A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

APPLICANTS:      Lauffer et al.  
U.S.S.N.:        Not Yet Assigned

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0725, Reference No. VPI/98-18 DIV US.

Respectfully submitted,



Nandakumar Govindaswamy, Ltd. Recognition  
Attorney for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139-4242  
Tel: (617) 444-6619  
Fax: (617) 444-6483

Express Mail No. EV 317 172 776 US

Date of Deposit: August 1, 2003

<b>Modified Form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	Not Yet Assigned
	<b>Filing Date</b>	Herewith
	<b>First Named Inventor</b>	David Lauffer
	<b>Group Art Unit</b>	1625
	<b>Examiner Name</b>	C. Aulakh
	<b>Attorney Docket Number</b>	VPI-98-18 DIV US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1*	5,773,458	30-Jun-98	Sabb, et al.			17-Oct-1997

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B1*		WO 95/03302	SmithKline Beecham PLC	02-Feb-1995		
	B2*		0 398 629 A2	Merck Sharp & Dohme Ltd.	22-Nov-1990		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1*	Bulacinski, A.B., et al., "Synthesis of Acyclic and Heterocyclic Derivatives of 2-Carboxyquinuclidine. VII.", Acta Polonia Pharmaceutica, Drug Research, 51(6):489-492 (1994).
	C2*	Biniecki, S., et al., "Synthesis of (R), (S)-Phenylalkylamides of Quinuclidine-2-carboxylic Acid and Their Reduction to Amines.", p. 740, column 1, XP002150143 abstract & ACTA Polonia Pharmaceutica, 38(3):293-296 (1981).
	C3*	Binecki, S., et al., "Synthesis of R, S-Phenylalkylamides of Quinuclidine-3-carboxylic Acids and their Reduction to Amines", p. 56, column 2, XP002150144 abstract & ACTA Polonia Pharmaceutica, 38(6):641-645 (1981).
	C4*	Bulackinski, A., et al., "Synthesis of Acyclic and Heterocyclic Derivatives of 2-Carboxyquinuclidine.", p. 614, column 2, XP002150145 abstract & ACTA Polonia Pharmaceutica, 46(5):435-439 (1989).

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. 10/039,886, filed January 3, 2002, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Express Mail No. EV 317 172 776 US

Date of Deposit: August 1, 2003

<b>Modified Form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	Not Yet Assigned
	<b>Filing Date</b>	Herewith
	<b>First Named Inventor</b>	David Lauffer
	<b>Group Art Unit</b>	1625
	<b>Examiner Name</b>	C. Aulakh
	<b>Attorney Docket Number</b>	VPI-98-18 DIV US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1*	5,773,458	30-Jun-98	Sabb, et al.			17-Oct-1997

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1*	WO 95/03302	SmithKline Beecham PLC	02-Feb-1995	
	B2*	0 398 629 A2	Merck Sharp & Dohme Ltd.	22-Nov-1990	

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1*	Bulacinski, A.B., et al., "Synthesis of Acyclic and Heterocyclic Derivatives of 2-Carboxyquinuclidine. VII.", Acta Polonia Pharmaceutica, Drug Research, 51(6):489-492 (1994).
	C2*	Biniecki, S., et al., "Synthesis of (R), (S)-Phenylalkylamides of Quinuclidine-2-carboxylic Acid and Their Reduction to Amines.", p. 740, column 1, XP002150143 abstract & ACTA Polonia Pharmaceutica, 38(3):293-296 (1981).
	C3*	Binecki, S., et al., "Synthesis of R, S-Phenylalkylamides of Quinuclidine-3-carboxylic Acids and their Reduction to Amines", p. 56, column 2, XP002150144 abstract & ACTA Polonia Pharmaceutica, 38(6):641-645 (1981).
	C4*	Bulackinski, A., et al., "Synthesis of Acyclic and Heterocyclic Derivatives of 2-Carboxyquinuclidine.", p. 614, column 2, XP002150145 abstract & ACTA Polonia Pharmaceutica, 46(5):435-439 (1989).

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. 10/039,886, filed January 3, 2002, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.